Elucidating the prognostic significance of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese patients with metastatic colorectal cancer

Asia-Pacific Journal of Clinical Oncology

Volumn 11, Issue 2, 2015, Pages 160-169

  Ma, Brigette B ^a   Mo, Frankie ^a   Tong, Joanna H ^b   Wong, Ashley ^a   Wong, S C Cesar ^a,c   Ho, Wing M ^a   Wu, Cherry ^d   Lam, Polly W Y ^e   Chan, K F ^f   Chan, Timothy S K ^g   Tsui, Wilson M S ^h   Tsang, Alex K H ⁱ   Fung, Mandy N S ^j   Chan, Anthony T C ^a   To, Ka Fai ^b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c HONG KONG POLYTECHNIC UNIVERSITY   (Hong Kong)

^d ALICE HO MIU LING NETHERSOLE HOSPITAL   (Hong Kong)

^e QUEEN ELIZABETH HOSPITAL   (Hong Kong)

^f TUEN MUN HOSPITAL   (Hong Kong)

^g KWONG WAH HOSPITAL   (Hong Kong)

^h Caritas Medical Centre Hong Kong   (Hong Kong)

ⁱ Yan Chai Hospitalabstr LBA3 ^*  (Hong Kong)

^j UNITED CHRISTIAN HOSPITAL   (Hong Kong)

more..

Author keywords

BRAF; Chinese; KRAS; NRAS; PIK3CA mutations

Indexed keywords

B RAF KINASE; BEVACIZUMAB; CETUXIMAB; IRINOTECAN; OXALIPLATIN; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; RAS PROTEIN;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CHINESE; COHORT ANALYSIS; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MONOTHERAPY; ONCOGENE; ONCOGENE K RAS; ONCOGENE N RAS; ONCOGENE PIK3CA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIMARY TUMOR; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE; WILD TYPE; ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; COLORECTAL TUMOR; GENETICS; METABOLISM; METASTASIS; MIDDLE AGED; MUTATION; PATHOLOGY; PROGNOSIS; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; PHOSPHATIDYLINOSITOL 3-KINASES; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84928824791     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/ajco.12342     Document Type: Article

References (45)

1. Law CK, Mang O. Cancer incidence in Hong Kong. Med Bull U S Army Army 1st 2007; 12: 18-21.
2. Van Cutsem E, Kohne CH, Hitre E etal. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-1417.
3. Sobrero AF, Maurel J, Fehrenbacher L etal. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 2311-2319.
4. Jonker DJ, O'Callaghan CJ, Karapetis CS etal. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007; 357: 2040-2048.
5. Douillard JY, Siena S, Cassidy J etal. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010; 28: 4697-4705.
6. Peeters M, Price TJ, Cervantes A etal. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010; 28: 4706-4713.
7. Van Cutsem E, Peeters M, Siena S etal. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25: 1658-1664.
8. Bardelli A, Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 2010; 28: 1254-1261.
9. Ciardiello F, Lenz H, Kohne C etal. Effect of KRAS and NRAS mutational status on first-line treatment with FOLFIRI plus cetuximab in patients with metastatic colorectal cancer (mCRC): New results from the CRYSTAL trial. J Clin Oncol 2014; 32 (suppl 3; abstr LBA443).
10. Douillard JY, Oliner KS, Siena S etal. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2014; 369: 1023-1034.
11. Peeters MOK, Price T, Cervantes A etal. Analysis of KRAS/NRAS mutations in phase 3 study 20050181 of panitumumab (pmab) plus FOLFIRI versus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC). J Clin Oncol 2014; 32 (Suppl 3): abstr LBA387.
12. De Roock W, Claes B, Bernasconi D etal. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2011; 11: 753-762.
13. Price TJ, Hardingham JE, Lee CK etal. Impact of KRAS and BRAF gene mutation status on outcomes from the phase III AGITG MAX trial of capecitabine alone or in combination with bevacizumab and mitomycin in advanced colorectal cancer. J Clin Oncol 2011; 29: 2675-2682.
14. Sartore-Bianchi A, Martini M, Molinari F etal. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 2009; 69: 1851-1857.
15. Jhawer M, Goel S, Wilson AJ etal. PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res 2008; 68: 1953-1961.
16. Ma BB, Hui EP, Mok TS. Population-based differences in treatment outcome following anticancer drug therapies. Lancet Oncol 2010; 11: 75-84.
17. Janakiraman M, Vakiani E, Zeng Z etal. Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res 2010; 70: 5901-5911.
18. Smith G, Bounds R, Wolf H, Steele RJ, Carey FA, Wolf CR. Activating K-Ras mutations outwith "hotspot" codons in sporadic colorectal tumours - implications for personalised cancer medicine. Br J Cancer 2010; 102: 693-703.
19. Loupakis F, Ruzzo A, Cremolini C etal. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer 2009; 101: 715-721.
20. De Roock W, Jonker DJ, Di Nicolantonio F etal. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 2010; 304: 1812-1820.
21. Mao C, Zhou J, Yang Z etal. KRAS, BRAF and PIK3CA mutations and the loss of PTEN expression in Chinese patients with colorectal cancer. PLoS ONE 2012; 7: e36653.
22. Gao J, Wang TT, Yu JW, Li YY, Shen L. Wild-type KRAS and BRAF could predict response to cetuximab in Chinese colorectal cancer patients. Chin J Cancer Res 2011; 23: 271-275.
23. Li FH, Shen L, Li ZH etal. Impact of KRAS mutation and PTEN expression on cetuximab-treated colorectal cancer. World J Gastroenterol 2010; 16: 5881-5888.
24. Liou JM, Wu MS, Shun CT etal. Mutations in BRAF correlate with poor survival of colorectal cancers in Chinese population. Int J Colorectal Dis 2011; 26(11): 1387-1395.
25. Sohn BS, Kim TW, Lee JL etal. The role of KRAS mutations in predicting the efficacy of cetuximab-plus-irinotecan therapy in irinotecan-refractory Korean metastatic colorectal cancer patients. Oncology 2009; 77: 224-230.
26. Soeda H, Shimodaira H, Watanabe M etal. Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer. Int J Clin Oncol 2013; 18(4): 670-677.
27. Nakanishi R, Harada J, Tuul M etal. Prognostic relevance of KRAS and BRAF mutations in Japanese patients with colorectal cancer. Int J Clin Oncol 2013; 18(6): 1042-1048.
28. Imamura Y, Morikawa T, Liao X etal. Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers. Clin Cancer Res 2012; 18: 4753-4763.
29. Sylvester BE, Huo D, Khramtsov A etal. Molecular analysis of colorectal tumors within a diverse patient cohort at a single institution. Clin Cancer Res 2011; 18: 350-359.
30. Peeters M, Douillard JY, Van Cutsem E etal. Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab. J Clin Oncol 2013; 31: 759-765.
31. Liao X, Lochhead P, Nishihara R etal. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med 2013; 367: 1596-1606.
32. Irahara N, Baba Y, Nosho K etal. NRAS mutations are rare in colorectal cancer. Diagn Mol Pathol 2010; 19: 157-163.
33. Therkildsen C, Bergmann TK, Henrichsen-Schnack T, Ladelund S, Nilbert M. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: a systematic review and meta-analysis. Acta Oncol 2014; 53(7): 852-864.
34. Hutchins G, Southward K, Handley K etal. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol 2012; 29: 1261-1270.
35. Sinicrope FMM, Smyrk T, Thibodeau S etal. Prognostic impact of BRAF and KRAS mutations and their relationship to DNA mismatch repair (MMR) status in 2, 686 stage III colon cancer patients (pts) treated in a phase III study of adjuvant FOLFOX with or without cetuximab: NCCTG N0147. J Clin Oncol 2012; 30 (suppl; abstr 3514).
36. Richman SD, Seymour MT, Chambers P etal. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol 2009; 27: 5931-5937.
37. Lin YL, Liau JY, Yu SC etal. KRAS mutation is a predictor of oxaliplatin sensitivity in colon cancer cells. PLoS ONE 2013; 7: e50701.
38. Bokemeyer C, Van Cutsem E, Rougier P etal. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer 2012; 48: 1466-1475.
39. Souglakos J, Philips J, Wang R etal. Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. Br J Cancer 2009; 101: 465-472.
40. Tol J, Dijkstra JR, Klomp M etal. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. Eur J Cancer 2012; 46: 1997-2009.
41. Roth AD, Tejpar S, Delorenzi M etal. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010; 28: 466-474.
42. Prenen H, De Schutter J, Jacobs B etal. PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clin Cancer Res 2009; 15: 3184-3188.
43. Van Cutsem E, Dicato M, Arber N etal. Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009. Ann Oncol 2010; 21 (Suppl 6): vi1-10.
44. Calonge N, Fisher NL, Berg AO etal. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy? Genet Med 2013; 15(7): 517-527.
45. Behl AS, Goddard KA, Flottemesch TJ etal. Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer. J Natl Cancer Inst 2012; 104: 1785-1795.